Mismatch repair–deficient, locally advanced rectal cancer was completely treated in 12 patients by single-agent treatment with dostarlimab (Jemperli, monoclonal antibody) programmed death receptor-1 ( PD-1) blockade. These patients have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) showed no evidence of tumor on magnetic resonance imaging, 18 F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. No patients had received chemoradiotherapy or surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). Amazingly no adverse events of grade 3 or higher. JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody approved by FDA for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced: • endometrial cancer, as determined by an FDA-approved test, that has ...
This is a blog by Kaleem Mohammed, PhD, for those who want to understand little more about health conditions and medications. He is a community pharmacist and chronic disease educator for Salt Lake County Health dept. As an Asst. Prof at University of Utah, he taught pharmacology to MD, PA and PharmD students. His Hypoxia Inducible Factor-1 research has been cited by Drs. Gregg Samenza/EJ Corey (Nobel, 2019/1990)